(1-Hydroxy-3-octadecanoyloxypropan-2-yl) docosanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油脂
• 英文名称: (1-Hydroxy-3-octadecanoyloxypropan-2-yl) docosanoate
• 化学式: C₄₃H₈₄O₅
• 分子量: 681.1
• InChiKey: IMCGKQALNIGVRI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  18.4
• 重原子数：
  48
• 可旋转键数：
  42
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS DESTINÉS AU TRAITEMENT D'ÉTATS PATHOLOGIQUES ASSOCIÉS À UNE ACTIVITÉ NLRP
  申请人：IFM TRE INC

  公开号：WO2019023145A1

  公开（公告）日：2019-01-31

  In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.

  在一个方面，特色化合物AA的公式，或其药学上可接受的盐。在公式AA中显示的变量如索引中所定义。公式AA的化合物是NLRP3活性调节剂，因此可用于治疗代谢性疾病（例如2型糖尿病、动脉粥样硬化、肥胖或痛风）、中枢神经系统疾病（例如阿尔茨海默病、多发性硬化症、肌萎缩性侧索硬化或帕金森病）、肺部疾病（例如哮喘、慢性阻塞性肺疾病或肺部特发性纤维化）、肝脏疾病（例如NASH综合征、病毒性肝炎或肝硬化）、胰腺疾病（例如急性胰腺炎或慢性胰腺炎）、肾脏疾病（例如急性肾损伤或慢性肾损伤）、肠道疾病（例如克罗恩病或溃疡性结肠炎）、皮肤疾病（例如牛皮癣）、肌肉骨骼疾病（例如硬皮病）、血管障碍（例如巨细胞动脉炎）、骨骼疾病（例如骨关节炎、骨质疏松症或骨质增生疾病）、眼部疾病（例如青光眼或黄斑变性）、病毒感染引起的疾病（例如HIV或艾滋病）、自身免疫疾病（例如类风湿性关节炎、系统性红斑狼疮或自身免疫性甲状腺炎）、癌症或衰老。
• [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS DESTINÉS AU TRAITEMENT D'ÉTATS PATHOLOGIQUES ASSOCIÉS À UNE ACTIVITÉ DE NLRP
  申请人：IFM TRE INC

  公开号：WO2019023147A1

  公开（公告）日：2019-01-31

  In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured.The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.

  在一方面，特征在于公式AA的化合物，或其药用可接受的盐。公式AA中所示的变量如权利要求中所定义。公式AA的化合物是NLRP3活性的调节剂，因此，可用于治疗代谢紊乱（例如2型糖尿病、动脉硬化、肥胖或痛风）、中枢神经系统疾病（例如阿尔茨海默病、多发性硬化症、肌萎缩侧索硬化症或帕金森病）、肺病（例如哮喘、慢性阻塞性肺病或特发性肺纤维化）、肝病（例如非酒精性脂肪肝炎、病毒性肝炎或肝硬化）、胰腺病（例如急性胰腺炎或慢性胰腺炎）、肾病（例如急性肾损伤或慢性肾损伤）、肠病（例如克罗恩病或溃疡性结肠炎）、皮肤病（例如银屑病）、肌肉骨骼疾病（例如硬皮病）、血管障碍（例如巨细胞动脉炎）、骨骼疾病（例如骨关节炎、骨质疏松症或骨石化病）、眼病（例如青光眼或黄斑变性）、由病毒感染引起的疾病（例如HIV或艾滋病）、自身免疫病（例如类风湿性关节炎、系统性红斑狼疮或自身免疫性甲状腺炎）、癌症或衰老。
• Methylene Blue Derivatives
  申请人：Rariy V. Roman

  公开号：US20070116757A1

  公开（公告）日：2007-05-24

  Pharmaceutical compositions comprising a fatty acid salt, a dicarboxylic acid salt, an alkyl sulfate salt, an aryl sulfate salt or an alkyl aryl sulfonate salt of methylene blue or a derivative of methylene blue are described herein. The compositions are preferably administered orally and can be administered as tablets, soft or hard shell capsules (e.g. soft gelatin capsules), suspensions or solutions. The composition can also be formulated as a suppository or enema or rectal administration. The compositions further comprise a pharmaceutically acceptable carrier and optionally one or more pharmaceutically acceptable excipients. Suitable excipients include diluents, binders, plasticizers, lubricants, disintegrants, colorants, stabilizers, surfactants, and combinations thereof. The fatty acid salts, alkyl sulate salts, aryl sulfate salts or alkyl aryl sulfonate salts can be co-mixed or co-melted with one or more fatty acids to make more hydrophobic compositions, which may result in less staining formulations. The compositions can be formulated for immediate release, controlled release such as extended release, delayed release, and pulsatile release, or combinations thereof. In one embodiment, the derivative of methylene blue is methylene dodecylsulfate.

  本文描述了包含脂肪酸盐、二羧酸盐、烷基硫酸盐、芳基硫酸盐或烷基芳基磺酸盐的甲蓝或甲蓝衍生物的制药组合物。这些组合物最好是口服给药，可以制成片剂、软壳或硬壳胶囊（例如软明胶胶囊）、悬浮液或溶液进行给药。该组合物也可以制成栓剂或灌肠剂或直肠给药。这些组合物还包括一种药用可接受载体，以及可选地一种或多种药用可接受的辅料。适用的辅料包括稀释剂、粘结剂、增塑剂、润滑剂、崩解剂、色素、稳定剂、表面活性剂以及它们的组合。脂肪酸盐、烷基硫酸盐、芳基硫酸盐或烷基芳基磺酸盐可以与一种或多种脂肪酸共混或共熔，制成更疏水的组合物，这可能导致更少的染色配方。这些组合物可以制成即时释放、控制释放（如延长释放）、延迟释放和脉冲释放，或者以上述的组合形式。在一个实施例中，甲蓝的衍生物是十二烷基硫酸甲蓝。
• Triglycerides containing saturated fatty acids having 20 to 24 carbon atoms useful in lowering blood cholesterol levels
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP0422490A2

  公开（公告）日：1991-04-17

  Triglyceride fats based on very long chain C₂₀ to C₂₄ saturated fatty acid triglycerides that are effective in lowering blood cholesterol levels are disclosed. These triglyceride fats are useful in pharmaceutical compositions in effective unit dosage amounts for inhibiting cholesterol absorption and in methods for treating hypercholesterolemia. These triglyceride fats are also useful, in whole or in part, in the triglyceride fat component of fat-containing food compositions. These fat-containing food compositions can be used as part of a dietary method or regimen for lowering blood cholesterol levels.

  本发明公开了可有效降低血液胆固醇水平的基于超长链 C₂₀ 至 C₂₄ 饱和脂肪酸甘油三酯的甘油三酯脂肪。这些甘油三酯脂肪可用于有效单位剂量的药物组合物，以抑制胆固醇的吸收，并用于治疗高胆固醇血症的方法。这些甘油三酯脂肪还可全部或部分用于含脂肪食品组合物中的甘油三酯脂肪成分。这些含脂食品组合物可用作降低血液胆固醇水平的饮食方法或方案的一部分。
• Methods and compositions for treating conditions associated with an abnormal inflammatory responses
  申请人：First Wave Bio, Inc.

  公开号：US10292951B2

  公开（公告）日：2019-05-21

  This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

  本公开的化学实体（例如，具有线粒体解偶联剂活性的化合物或其药学上可接受的盐和/或水合物和/或共晶体；例如，化合物，如烟酰胺或其药学上可接受的盐和/或水合物和/或共晶体；例如、化合物，如尼可刹米类似物，或其药学上可接受的盐和/或水合物和/或共晶体），这些化合物可用于治疗受试者（如人类）中以异常炎症反应（如炎症性肠病）为特征的病理学的一种或多种症状。本公开内容还包括组合物以及使用和制造组合物的其他方法。